Evidence map›Paper›PMID 38735175›Full record

ArticleClinics (Sao Paulo, Brazil)2024

Prognostic nomogram based on pre-treatment HALP score for patients with advanced non-small cell lung cancer.

Shan Gao, Qin Huang, Suosu Wei, Yanru Lv, Yanyan Xie, Yanrong Hao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinics (Sao Paulo, Brazil), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Revealing the prognostic landscape of hemoglobin, albumin, lymphocyte, and platelet score in patients with lung cancer: a pooled analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shan GaoMedical Oncology Division 1, Clinical Oncology Center, People' s Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China; The First Clinical Medical College, Jinan University, Guangzhou, Guangdong, China.
Qin HuangDepartment of Oncology and Chemotherapy, Yulin Red Cross Hospital, Yulin, Guangxi, China.
Suosu WeiDepartment of Scientific Cooperation of Guangxi Academy of Medical Sciences, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.
Yanru LvDepartment of Scientific Cooperation of Guangxi Academy of Medical Sciences, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.
Yanyan XieMedical Oncology Division 1, Clinical Oncology Center, People' s Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.
Yanrong HaoMedical Oncology Division 1, Clinical Oncology Center, People' s Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China. Electronic address: yrhao@gxams.org.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo explore the correlation of pre-treatment Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) score with the prognosis of patients with advanced Non-Small Cell Lung Cancer (NSCLC) undergoing first-line conventional platinum-based chemotherapy.

methodsIn this retrospective cohort study, 203 patients with advanced NSCLC were recruited from January 2017 to December 2021. The cut-off value for the HALP score was determined by Receiver Operating Characteristic (ROC) curve analysis. The baseline characteristics and blood parameters were recorded, and the Log-rank test and Kaplan-Meier curves were applied for the survival analysis. In the univariate and multivariate analyses, the Cox regression analysis was carried out. The predictive accuracy and discriminative ability of the nomogram were determined by the Concordance index (C-index) and calibration curve and compared with a single HALP score by ROC curve analysis.

resultsThe optimal cut-off value for the HALP score was 28.02. The lower HALP score was closely associated with poorer Progression-Free Survival (PFS) and Overall Survival (OS). The male gender and other pathological types were associated with shorter OS. Disease progression and low HALP were correlated with shorter OS and PFS. In addition, nomograms were established based on HALP scores, gender, pathology type and efficacy rating, and used to predict OS. The C-index for OS prediction was 0.7036 (95% CI 0.643 to 0.7643), which was significantly higher than the C-index of HALP at 6-, 12-, and 24-months.

conclusionThe HALP score is associated with the prognosis of advanced NSCLC patients receiving conventional platinum-based chemotherapy, and the nomogram established based on the HALP score has a better predictive capability for OS.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsNomogramsAdultAgedBlood PlateletsFemaleHemoglobinsHumansKaplan-Meier EstimateLymphocyte CountMaleMiddle AgedNeoplasm StagingPlatelet CountPrognosisHemoglobinsSerum AlbuminHemoglobin-Albumin-Lymphocyte-Platelet ScoreNomogramNon-small cell lung cancer (NSCLC)Prediction modelSurvival analysis

Identifiers

PMID38735175
PMCPMC11101934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.